Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate
On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…
Regeneron announced U.S. Government agreement to purchase additional REGEN-COV antibody cocktail
On Sept. 14, 2021, Regeneron announced an agreement with the U.S. Department of Health and Human Services and…
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATY
On Sept. 6, 2021, Pfizer and BioNTech announced that they had submitted a variation to the European Medicines…
INOVIO received authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate, INO-4800 in Brazil
On Aug. 26, 2021, Inovio Pharma announced that it had received regulatory authorization from Brazil’s ANVISA (Agencia Nacional…
Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and Older
On Aug. 25, 2021, Pfizer and BioNTech announced the initiation of a supplemental Biologics License Application (sBLA) to…
Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and older
On Aug. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…
Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variants
On Jul. 29, 2021, Cocrystal Pharma announced that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 vacation Destinations
Planning a Summer vacation? Where to go? How about going to one of those large events with tens…
Merck Announces FDA approval of VAXNEUVANCE for prevention of invasive pneumococcal disease
On Jul. 16, 2021, Merck announced the U.S. Food and Drug Administration (FDA) had approved VAXNEUVANCE (Pneumococcal 15-valent…
Vibativ effectively helped treat secondary bacterial infections in COVID-19 patients
On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin)…
Cocrystal’s COVID-19 antiviral CDI-45205 shown to be active against SARS-CoV-2 and prominent SARS-CoV-2 variants
On Jun. 14, 2021, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
RECOVERY trial found aspirin does not improve survival for patients hospitalised with COVID-19
On Jun. 8, 2021, the University of Oxford announced that the RECOVERY trial found aspirin does not improve…
Patient enrollment reached 90 percent in Innovation Pharma’s phase 2 clinical trial of brilacidin for COVID-19
On May 27, 2021, Innovation Pharma announced that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial…
Pfizer and BioNTech announced supplying EU with up to 1.8 billion additional doses of COMIRNATY
On May 20, 2021, Pfizer and BioNTech announced a new agreement with the European Commission (EC) to supply…
Pfizer and BioNTech submitted request to expand conditional marketing authorization of COMIRNATY in EU to adolescents
On Apr. 29, 2021, Pfizer and BioNTech announced they had submitted a variation to the Conditional Marketing Authorization…
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | Life Science History | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | USDA | Vaccine | WHO
COVID-19 science and reason
COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
Johnson & Johnson announced agreement with African Vaccine Acquisition Trust for COVID-19 vaccine candidate
On Mar. 29, 2021, Janssen Pharmaceutica announced that it had entered into an agreement with the African Vaccine…
Pfizer initiated phase 1 study of movel oral antiviral therapeutic agent against SARS-CoV-2
On Mar. 23, 2021, Pfizer announced that it was progressing to multiple ascending doses after completing the dosing…
COVID-19 | Pharmaceutical | Vaccine | WHO
WHO COVID-19 subcommittee announced safety signals related to AstraZeneca COVID-19 vaccine
On Mar. 17, 2021, the WHO reported that the AstraZeneca COVID-19 vaccine (including Covishield) continued to have a…
Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech submited COVID-19 vaccine stability data at standard freezer temperature to the FDA
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
Low-dose aspirin may improve pregnancy chances for women with one or two prior miscarriages
On Jan. 25, 2021, the National Institutes of Health (NIH) announced that in large clinical trial conducted worldwide,…
RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
Cocrystal Pharma selected lead compound for further development against Coronaviruses
On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…